BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22098159)

  • 1. Deregulation of Hippo kinase signalling in human hepatic malignancies.
    Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
    Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
    Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
    Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
    Kim W; Khan SK; Liu Y; Xu R; Park O; He Y; Cha B; Gao B; Yang Y
    Gut; 2018 Sep; 67(9):1692-1703. PubMed ID: 28866620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma.
    Hu H; Xu L; Luo SJ; Xiang T; Chen Y; Cao ZR; Zhang YJ; Mo Z; Wang Y; Meng DF; Yu L; Lin LZ; Zhang SJ
    Int J Med Sci; 2020; 17(13):1897-1908. PubMed ID: 32788868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
    Wong KF; Liu AM; Hong W; Xu Z; Luk JM
    Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
    Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
    J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
    Ahn EY; Kim JS; Kim GJ; Park YN
    Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma.
    LaQuaglia MJ; Grijalva JL; Mueller KA; Perez-Atayde AR; Kim HB; Sadri-Vakili G; Vakili K
    Sci Rep; 2016 Sep; 6():30238. PubMed ID: 27605415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
    Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
    J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
    Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
    Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S1P Stimulates Proliferation by Upregulating CTGF Expression through S1PR2-Mediated YAP Activation.
    Cheng JC; Wang EY; Yi Y; Thakur A; Tsai SH; Hoodless PA
    Mol Cancer Res; 2018 Oct; 16(10):1543-1555. PubMed ID: 29903770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.
    Wang C; Zhu ZM; Liu CL; He XJ; Zhang HY; Dong JH
    Mol Med Rep; 2015 Jun; 11(6):4101-8. PubMed ID: 25625370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Mimics Effects of Glypican-3 on CD81 and Promotes Development of Hepatocellular Carcinomas via Activation of Hippo Pathway in Hepatocytes.
    Xue Y; Mars WM; Bowen W; Singhi AD; Stoops J; Michalopoulos GK
    Am J Pathol; 2018 Jun; 188(6):1469-1477. PubMed ID: 29577937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.
    Nakanuma S; Tajima H; Okamoto K; Hayashi H; Nakagawara H; Onishi I; Takamura H; Kitagawa H; Fushida S; Tani T; Fujimura T; Kayahara M; Ohta T; Wakayama T; Iseki S; Harada S
    Int J Oncol; 2010 Apr; 36(4):793-800. PubMed ID: 20198321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.